Changes in Beneficial Ownership · 4
Erasca, Inc.
ERASNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-08-10
- Issuer
- Erasca, Inc.
- Issuer CIK
- 0001761918
- Trading symbol
- ERAS
Reporting owner 1
- Name
- Fuchs Charles S.
- Reporting owner CIK
- 0001719576
- Relationship
- Officer
- Officer title
- President, R&D
- Address
- C/O ERASCA, INC., 3115 MERRYFIELD ROW, SUITE 300, SAN DIEGO, CA, 92121
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy) | 18.12 | 2026-08-10 | A · Form 4 | 1,300,000[F1] | A | 0 | 2027-08-10[F2] | 2036-08-09 | Common Stock | 1,300,000 | 1,300,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The reported option award was granted in connection with the Reporting Person's commencement of employment. Of the total option award, 21,480 shares were granted under the Issuer's 2021 Incentive Award Plan, with a portion intended to qualify as an incentive stock option under Section 422 of the Internal Revenue Code to the extent permitted by law. The remaining 1,278,520 shares were granted as a nonqualified stock option under the Issuer's 2026 Employment Inducement Incentive Award Plan.↩ 1
- F2
- The reported option award vests as follows: 25% of the shares subject to the option will vest on the first anniversary of the date of grant, and the remaining 75% of the shares will vest in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date.↩ 1
Signature 1
- Signed
- /s/ Ebun S. Garner, as Attorney-in-Fact
- Date
- 2026-08-12
Company context
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.